Exelixis, Inc. (NASDAQ: EXEL) is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer.
Exelixis announced on Thursday the commercial availability of COMETRIQ® (cabozantinib) for the treatment of patients with progressive, metastatic medullary thyroid cancer approved by FDA on November 29, 2012. COMETRIQ (cabozantinib) is being distributed exclusively through Diplomat Specialty Pharmacy in the U.S.
Cabozantinib inhibits the activity of tyrosine kinases including RET, MET and VEGFR2. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.
Previously, Exelixis announced their oncology candidate, GDC-0973 (XL518), has commenced in a phase III study evaluating GDC-0973 in combination with Roche’s Zelboraf (vemurafenib). The multicenter, randomized, double-blind, placebo-controlled phase III trial will evaluate the safety and efficacy of GDC-0973 in combination with Zelboraf versus Zelboraf alone in treatment naïve BRAFV600 mutation positive patients with malignant melanoma (skin cancer).